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Statement of Principles for Health Care 
Journalists
Gary Schwitzer
In “The Commercialisation of Medical and Scientiﬁ  c 
Reporting” [1], Caulﬁ  eld calls on journalists to ask 
researchers about the nature of their funding and the 
ﬁ  nancial relationship of the researchers to the sponsor. This 
is just one principle addressed in a much broader “Statement 
of Principles” I wrote this past year for the Association of 
Health Care Journalists (http:⁄⁄www.ahcj.umn.edu). The 
statement is available online [2].  
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Accounting for Individual Differences 
in Risk of Alzheimer Disease
William Grant
Gatz’s statement, “At least half of the explanation for 
individual differences in susceptibility to Alzheimer disease 
is genetic” [1], is, in my opinion, incorrect. As the one who 
led the team debating Ashford and Mortimer, whose 2002 
article [2] supports this statement, at the 2001 conference 
on Alzheimer disease (AD) in Cincinnati (“Challenging 
Views of Alzheimer’s Disease”) [3], I think that the evidence 
that dietary and lifestyle factors explain the majority of the 
individual risk for AD in the US is very strong. My original 
paper in 1997 [4] found that total dietary fat and energy 
intake were the most important dietary risk factors, while ﬁ  sh 
and cereal intake were the most important risk reduction 
factors. These ﬁ  ndings have been generally conﬁ  rmed by 
Drs. Luchsinger and Morris and others. The reason I did 
my study was that the Honolulu Heart Study reported that 
Japanese American men in Hawaii had 2.5 times the risk of 
AD of native Japanese. African-Americans have about four 
times the risk of AD of native Nigerians. If genetics were the 
primary risk factor, those living in the US would have a risk 
of developing AD very similar to that of individuals living 
in their ancestral home. The reason this is not the case is 
that the American diet provides too much food, which is a 
particular problem for those genetically predisposed to AD.  
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Author’s Reply
Grant [1] describes as incorrect the statement that at least 
half of the explanation for individual differences in risk 
for Alzheimer disease is genetic. He suggests instead that 
dietary and lifestyle factors explain the majority of individual 
susceptibility to Alzheimer disease. 
The basis for asserting a 50% or greater role for genetics 
in Alzheimer disease risk comes from family studies and 
from twin studies. In family studies, ﬁ  rst-degree relatives of 
individuals with Alzheimer disease are at more than double 
the risk of Alzheimer disease compared to those with no 
affected relatives [2,3]. In twin studies, across different 
Scandinavian twin registries, estimates of heritability of 
Alzheimer disease range from 55% to over 70% [4].
Genetic risk undoubtedly represents the cumulative 
inﬂ  uence of many genes, including apolipoprotein E (APOE) 
and other genes not yet identiﬁ  ed. In particular, it appears 
that the magnitude of the genetic component of Alzheimer 
disease risk is similar across ethnic communities, but that 
different genetic factors may contribute differently to that risk 
in white, Latino, and African American families [5].
Further, there are interactions between genetic and 
environmental risks, for example, between the APOE e4 allele 
and high cholesterol [6] or head injury [7]. 
Clearly Alzheimer disease is the outcome of multiple 
genetic and multiple environmental inﬂ  uences, operating 
additively and interactively. If genetic effects account for 
half of individual differences in liability, then environmental 
inﬂ  uences also account for half of the variation in 
susceptibility. From a public health viewpoint, it is vital to 
identify those inﬂ  uences that are modiﬁ  able. Controlling 
blood pressure and avoiding head trauma are examples. 
However, it is also important to appreciate that individuals 
bring differences in genetic risk to the table.  
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Tumor Cell Recognition Efﬁ  ciency 
by T Cells
Daniel E. Speiser, Jean-Charles Cerottini, Pedro Romero
Stuge et al. report a detailed analysis of the ﬁ  ne speciﬁ  city of 
CD8+ T cells against tumor-associated antigen in melanoma 
patients [1]. They compared peptide-vaccination-driven with 
naturally arising T cell responses against the HLA-A*0201 
restricted melanoma peptide antigens M26 (derived from 
Melan-A/MART-1) and G209-2M (derived from gp100 
protein). A major endpoint of this study was in vitro tumor 
cell recognition by T cells. Fortunately, this is increasingly 
used as a “golden” standard in the assessment of tumor-
speciﬁ  c T cells. The authors suggest that spontaneously 
arising antigen-speciﬁ  c T cell populations are qualitatively 
different from those induced by vaccination with heteroclitic 
peptides (which are altered for increased HLA binding): 
tumor cell recognition was found in nearly all T cells from 
the former, but only in a minority from the latter. As reported 
previously, these results correlated with recognition efﬁ  ciency 
of antigenic peptides. We agree that this has considerable 
implications for immunotherapy and congratulate the 
authors for analyzing T cell recognition in great detail. 
However, in one point our own studies lead to different 
results: we repetitively found that the majority of T cells 
generated with the heteroclitic Melan-A M26 peptide were 
tumor reactive. This was the case for Melan-A-speciﬁ  c T cell 
populations generated in HLA-A*0201 transgenic mice [2], 
in vitro [3], and in melanoma patients [4]. The latter studies 
also assessed T cells from vaccination-site sentinel lymph 
nodes, containing T cells that are very likely selected and 
activated by vaccination and not by the tumor.
The authors point out correctly that tetramer+ T cells 
comprise many cells unable to recognize and kill tumor cells 
in an antigen-speciﬁ  c manner, presumably owing to low T 
cell receptor avidity to cognate antigen. An extreme case is 
naïve T cell populations, of which the majority are unable to 
recognize tumor cells, despite their speciﬁ  c binding to MHC/
peptide tetramers [5]. Therefore, it is crucial to exclude 
naïve T cells from studies analyzing tumor recognition. 
HLA-A*0201+ humans (healthy individuals and melanoma 
patients) have 0.07% ± 0.05% naïve Melan-A tetramer+ 
cells within peripheral blood CD8+ T cells [5,6]. The three 
patients studied by Stuge et al. had 0.23%, 0.12%, and 
0.50% Melan-A tetramer+ cells. Thus, one can estimate that 
the studied populations from the three patients contained 
approximately  30%, 60%, and 15% naïve Melan-A-speciﬁ  c 
T cells, respectively. This is only a rough estimate—tetramer 
analysis before vaccination and assessment of CD45RA/
CCR7 expression would give more insight. Nevertheless, it 
remains likely that the ﬁ  rst two patients had considerably 
more naïve cells than the third patient (i.e., the one without 
immunotherapy). In addition, naïve-derived CD8+ T cells 
have a higher clonogenic potential than activated Melan-A-
speciﬁ  c T cells from melanoma patients (unpublished data). 
This means that overrepresentation of clones derived from 
naïve CD8+ T cells is likely to occur when both naïve and 
activated antigen-speciﬁ  c CD8+ T cells co-exist in a given 
lymphocyte population. As mentioned, Stuge et al. found 
unexpected high frequencies of T cell clones not recognizing 
tumor cells in the two vaccinated patients. It is conceivable 
that this was due to the presumably high percentages of naïve 
Melan-A-speciﬁ  c cells present in the populations used for 
generating the clones, which would provide an explanation 
for the discrepancy with the results of our studies [2,3,4].
Ethical considerations limit vaccination studies in healthy 
humans. In patients, candidate antigens should therefore be 
tested with strong adjuvants [7], to increase the likelihood 
that the studied responses are predominantly vaccination-
driven, with only minor contribution of spontaneous T cell 
activation [8]. It would be desirable to directly compare 
vaccination with heteroclitic peptide versus vaccination 
with natural peptide. However, this is hampered by the lack 
of ex vivo detectable responses to native peptides owing 
to their low immunogenicity. Another option is to analyze 
clonal distributions (T cell receptors) of responding T cells 
extensively: Further support for the notion that spontaneous 
(tumor driven) responses have increased potential for tumor 
recognition would be obtained if mono/oligoclonal T cell 
repertoires are indeed signiﬁ  cantly more often found in 
spontaneous than vaccination-induced responses.
We certainly agree that vaccines must be optimized. 
Thus, more such studies are desirable, since they have 
high potential to lead to better understanding of the 
differences between clinically irrelevant and relevant T cell 
responses, and to rapidly identify the most promising vaccine 
formulations that can subsequently be tested in large-scale 
clinical trials.  
Daniel E. Speiser (daniel.speiser@hospvd.ch)
Jean-Charles Cerottini
Pedro Romero
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Authors’ Reply
Drs. Speiser, Cerottini, and Romero [1] correctly point out 
that CD8+ T cells from HLA-A*0201 melanoma patients 
and healthy donors may contain small populations (on 
average, 0.07% ± 0.05% in their publications [2,3]) that bind 
tetramers made with the heteroclitic Melan-A M26 peptide, 
and that such cells express a naïve phenotype (CD45RA+). 
We too observe this phenomenon in a portion of HLA-
A*0201 healthy donors and patients with melanoma that 
we analyze with M26 tetramers. Importantly, this is not seen 
in all subjects. These cells do not recognize the native M27 
peptide, and represent cross-reactive subsets of naïve CD8+ 
T cells of multiple speciﬁ  cities [4]. We routinely analyze 
all subjects pre-vaccination, and the four post-vaccination 
responses analyzed in our report [5] did not contain M26 
or gp100 tetramer-binding cells pre-vaccination (data not 
shown). Thus, it was unlikely that M26-cross-reactive cells 
spontaneously developed post-vaccination (not due to 
peptide vaccination) and were the basis of some of the low-
recognition-efﬁ  ciency MART-speciﬁ  c clones we analyzed. 
Furthermore, such a phenomenon has been seen only with 
M26 and not with the heteroclitic gp100 (G209-2M) peptide, 
so would not be a factor in the gp100-speciﬁ  c responses we 
analyzed.
The authors also point out that in their experience, 
they found that the majority of T cells generated with the 
heteroclitic Melan-A M26 peptide were tumor reactive, citing 
their studies in vitro [6], in mice [7], and in patients with 
melanoma [8]. We focus on their publication on patients 
with melanoma, as this is most directly relevant to our study. 
This report [8] focused on three patients with melanoma 
immunized with M26, and analyzed T cells from lymph 
nodes draining the vaccination site (vaccine-site sential nodes 
[VSSNs]). VSSNs from these three patients contained 0.11% 
(0.08%–0.15%) MART-speciﬁ  c T cells by tetramer staining. 
Importantly, contralateral lymph nodes in these subjects 
(distant from the vaccination site) also contained 0.06% 
(0.05%–0.09%) MART-speciﬁ  c T cells. With their reported 
background of less than 0.01%, this suggests the possibility 
of endogenous MART-speciﬁ  c T cells within lymph nodes in 
these subjects. These authors have shown in previous studies 
that endogenous MART-speciﬁ  c T cell responses frequently 
exist within lymph nodes, even in the absence of such cells in 
peripheral blood mononuclear cells [9]. Furthermore, these 
VSSN responses were analyzed only after two vaccinations, 
while the authors could not detect circulating MART-
speciﬁ  c T cells in any of these three patients even after six 
vaccinations. MART-speciﬁ  c T cell lines were generated via 
tetramer-guided sorting of VSSN cells from patients 2 and 
3, then individual clones generated via limiting dilution. 
They reported 16 of 17 clones killed A2+ MART+ melanoma 
targets. Without knowing the Vbeta usage of these clones and 
the Vbeta diversity of the parental MART-speciﬁ  c populations, 
it is difﬁ  cult to know what fraction of each response these 
clones accounted for in the two subjects, as we have done 
in our study. More importantly, these tumor-reactive clones 
analyzed may be derived from endogenous T cell responses, 
possibly ampliﬁ  ed by vaccination, rather than from de novo 
vaccine-elicited T cell responses. If so, these data would in fact 
ﬁ  t well with our ﬁ  ndings that endogenous responses consist 
mainly of cells with tumor-cytolytic potential that recognize 
the native peptide with high recognition efﬁ  ciency.
In our study [5], we analyzed in detail four vaccine-elicited 
T cell responses (two to M26 and two to G209-2M) via the 
generation of more than 200 cytotoxic T lymphocyte clones, 
and assessed the fraction of each response that these clones 
accounted for collectively by analyzing the Vbeta usage of 
each clone and the parental peptide-speciﬁ  c populations. 
From this, we showed that the vaccine-elicited T cells were 
diverse in their tumor-cytolytic potential, which correlated 
with their recognition efﬁ  ciency for the native peptides. It 
is important to point out that tumor-cytolytic T cells were 
present in these four subjects, but represented a signiﬁ  cantly 
lower fraction than those derived from endogenous 
responses. These data are consistent with those we recently 
reported using a different experimental approach—assessing 
the fraction of T cells in a tetramer+ population that 
degranulate (via CD107 mobilization) to tumor stimulation 
[10]. While generating individual cytotoxic T lymphocyte 
clones and analyzing each for tumor killing and recognition 
efﬁ  ciency, as we have done in this study, is the most deﬁ  nitive 
approach to analyze individual cells within an antigen-speciﬁ  c 
T cell response, this approach is extremely labor-intensive, 
and thus not feasible for large numbers of patients. As 
such, more rapid ﬂ  ow-cytometry-based methods, such as the 
CD107 mobilization assay and a new method to rapidly assess 
recognition efﬁ  ciency of a T cell population via differential 
TCR downregulation (H. E. Kohrt, C. T. Shu, S. P. Holmes, J. 
S. Weber, P. P. L., et al., unpublished data), will allow analysis 
of many more patients to various vaccine formulations and 
strategies. This knowledge will be vital to the improvement of 
future cancer immunotherapies.  
Tor B. Stuge
Peter P. Lee (ppl@stanford.edu)
Stanford University
Standford, California, United States of America
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Cholesterol, Statins, and Alzheimer 
Disease
Alexei R. Koudinov, Temirbolat T. Berezov
After reading the excellent research article by Pedrini et 
al. [1] and the associated synopsis [2], one may conclude 
that the only pathway of statins’ effect on Alzheimer 
disease (AD) is the regulation of amyloid precursor 
protein (APP) processing and amyloid-β protein (Aβ) 
generation. The moderation is provided in the research 
article’s patient summary, reminding that “statins are 
likely to inﬂ  uence the risk for Alzheimer disease by several 
different pathways.” What are these other pathways? It is 
essential to note that in addition to APP processing and 
Aβ chemistry being modulated by statins, ﬁ  ne tuning of 
cholesterol homeostasis also affects cholinergic function, 
ionotropic and metabotropic receptors, tau phosphorylation, 
neural oxidative stress reactions, and other features of 
neurodegeneration (reviewed in [3]). Moreover, precise 
regulation of neural cholesterol dynamics and supply is itself 
essential for synapse function, plasticity, and behaviour [3]. 
These data suggest that in addition to its role in sporadic AD, 
cholesterol homeostasis break is the unifying primary cause 
of neuromuscular diseases, Niemann-Pick type C disease, 
and Down syndrome, and explains why rare cases of familial 
AD (associated with mutations in APP and presenilin genes) 
are translated into Alzheimer’s via membrane cholesterol 
sensitivity of APP processing by secretases and Aβ generation. 
Also important, is the synopsis’s [2] apparently outdated 
dividing of APP processing into “harmful” (Aβ-generating) 
and “healthy” (non-amyloidogenic). One should be cautious 
in calling Aβ a harmful molecule. This is because several 
recent studies have illuminated an essential function for 
amyloidogenic processing of APP and Aβ in neurons [4] 
and synapses [5]. In this context, the reciprocal effect of 
Aβ on cholesterol synthesis, cellular uptake, efﬂ  ux, and 
esteriﬁ  cation, and its relation to the experimental restoration 
of long-term potentiation (LTP, a synaptic plasticity measure) 
may represent one of the poorly comprehended physiological 
functions of Aβ [6,7].  
Alexei R. Koudinov (koudinov@neurobiologyoﬂ  ipids.org)
Temirbolat T. Berezov
Russian Academy of Medical Sciences
Moscow, Russia
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Authors’ Reply
We appreciate the note from Drs. Koudinov and Berezov 
[1]. In our opinion, no model has yet been presented that 
plausibly accounts for all the data on statins, cholesterol, 
amyloid-β protein (Aβ), and Alzheimer disease. In our 
paper [2], we present evidence that the isoprenoid 
pathway contributes to statin-activated shedding of the APP 
ectodomain in cultured cells. We do not yet know which 
(if any) other “cholesterol-related” Alzheimer phenomena 
are also attributable to modulation of isoprenoids, Rho, or 
ROCK. 
Previously, conventional wisdom held that Aβ load and 
hypercholesterolemia were directly related, based on 
observations that high-fat diet aggravated amyloid pathology 
in plaque-forming mice [3,4,5]. More recently, however, 
the formulation that statins act simply via cholesterol-
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lowering fails to account for several observations that cannot 
immediately be reconciled, either with the original “dogma” 
or with each other.
First, Fagan et al. [6] questioned the role of cholesterol as 
the ﬁ  nal common pathway in Aβ load speciﬁ  cation, since, 
in their experiments, low cholesterol per se apparently had 
no impact on brain Aβ load in plaque-forming transgenic 
mice. Then, equally puzzling pharmacological data emerged. 
Atorvastatin was shown to lower brain amyloid load and Aβ 
levels, but brain cholesterol levels were unaffected by the drug 
[7].  In an apparent complete contradiction with the original 
observations, now, some investigators have been able to devise 
circumstances under which there is an inverse relationship 
between cholesterol and Aβ, with low neuronal cholesterol 
increasing Aβ generation [8], and vice versa [9]. These newer 
observations are unexpected and extremely puzzling, and no 
comprehensive explanation has yet emerged.
For those readers seeking an update on this challenging 
area, we would direct your attention to the Alzheimer 
Research Forum Web page (http:⁄⁄www.alzforum.org/new/
detailprint.asp?id=1135), where you will ﬁ  nd an excellent 
review of the literature as well as a series of evaluations of 
how our data ﬁ  t into existing scenarios and models regarding 
cholesterol, statins, cerebral amyloidosis, and the cognitive 
failure of Alzheimer disease.  
Sam Gandy (samgandy@earthlink.net)
Farber Institute for Neurosciences, Thomas Jefferson University 
Philadelphia, Pennsylvania, United States of America
Suzana Petanceska
Nathan Kline Institute at New York University
Orangeburg, New York, United States of America
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Erick H. Turner [1] notes that “ClinicalTrials.gov, a registry 
authorized by the Food and Drug Modernization Act of 
1997, appears not to be comprehensive.” While we await the 
creation of clinical trials registry and results databases that are 
truly comprehensive, innovative efforts to provide convenient 
access to credible information about known existing clinical 
trials need to continue. A Canadian example is provided by 
OntarioCancerTrials.ca, a consumer-oriented site developed 
by the Ontario Cancer Research Network (OCRN), with 
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